## PFE: Pfizer, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.1% below STRENGTH zone (3.0-6.0%); PEG 14.22 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($24.73)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)**
- Source: ts2.tech | 20251215T130835 | Neutral | Relevance: 100%
- Pfizer (PFE) stock is trading around $25.85, ahead of its 2026 guidance call set for Dec. 16. The company recently declared a $0.43 quarterly dividend, announced a licensing agreement for an early-stage GLP-1 obesity candidate with YaoPharma, and continues to manage cost-cutting initiatives and pipeline momentum in oncology. Investors are closely watching for clarity on post-COVID growth, the impact of new acquisitions, and the company's strategy amid evolving regulatory landscapes, such as potential "black box" warnings for COVID-19 vaccines.

**2. 47,996 Shares in Pfizer Inc. $PFE Acquired by MASTERINVEST Kapitalanlage GmbH**
- Source: MarketBeat | 20251215T120848 | Neutral | Relevance: 100%
- MASTERINVEST Kapitalanlage GmbH recently acquired 47,996 shares of Pfizer Inc. ($PFE) in the second quarter, valued at approximately $1.163 million. This purchase is part of broader institutional investment activity in Pfizer, with other major investors like Vanguard Group Inc. and Geode Capital Management LLC also increasing their stakes. Analysts have issued a consensus "Hold" rating for Pfizer, with a target price of $28.33.

**3. Pfizer Stock (PFE) News and Forecast for Dec. 14, 2025: Dividend, Obesity Deal, Oncology Catalysts, and What Analysts Expect Next**
- Source: ts2.tech | 20251215T050831 | Neutral | Relevance: 100%
- Pfizer Inc. (PFE) is navigating a "reset" period, balancing a high dividend yield with significant catalysts and challenges. The article details recent positive developments, including a declared $0.43 dividend, promising oncology data from Tukysa, and a new GLP-1 candidate from YaoPharma, alongside ongoing cost-cutting efforts. However, investors also face headwinds from potential COVID-19 vaccine policy changes, patent expiration pressures, and geopolitical scrutiny of cross-border deals.

**4. Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open**
- Source: ts2.tech | 20251213T010857 | Neutral | Relevance: 100%
- Pfizer Inc. (NYSE: PFE) stock saw a modest after-hours move on December 12, 2025, after a busy day of news including a newly declared $0.43 quarterly dividend, reports of a potential FDA "black box" warning for COVID-19 vaccines, and positive late-stage oncology data for its breast-cancer drug Tukysa. Investors will be looking towards Pfizer's December 16 guidance call, which could provide a more significant catalyst than Friday's headlines. Morgan Stanley maintained an "Equal-Weight" rating on PFE but lowered its price target to $28 from $32.

**5. Pfizer Declares First-Quarter 2026 Dividend**
- Source: Business Wire | 20251212T170843 | Somewhat-Bullish | Relevance: 100%
- Pfizer Inc. has announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company's common stock. This dividend is payable on March 6, 2026, to shareholders of record as of January 23, 2026, marking the 349th consecutive quarterly dividend paid by Pfizer. The company highlighted its commitment to extending and improving patients' lives through science and innovative therapies.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $28 | $32 | -12% |
| 2025-11-24 | Guggenheim | $35 | $33 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-11-24 | Guggenheim | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 11 ($0.22M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 31.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.2%)
- Blackrock Inc.: 8.8% (+0.5%)
- State Street Corpora: 5.3% (+0.9%)
- Geode Capital Manage: 2.3% (+1.2%)
- Morgan Stanley: 1.3% (+6.6%)

### Key Risks

1. Valuation stretched: PEG 14.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +2.3% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 14.22 signals overvaluation risk, limited margin of safety. Quality metrics strong (margin 16%). Balance sheet: $4.0B free cash flow. Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $147.0B |
| Beta | 0.42 |
| 52W Range | $20.92 - $27.69 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 14.22 |
| Forward P/E | 8.4 |
| Current P/E | 8.3 |
| YoY Growth | -2.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.2% to 2.1% (+2.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.9pp (needs >3.0% for momentum thesis). MRS_5 at 1.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 56. OFD pattern: +DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.11% (CS: 54) | Neutral |
| RSI_14 | 56.3 | Neutral |
| MACD Histogram | 0.02 | Bullish |
| vs SMA20 | 1.017x | Above |
| vs SMA50 | 1.028x | Above |
| vs SMA200 | 1.053x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $25.85
- **Stop Loss:** $24.73 (4.3% risk)
- **Target:** $26.97 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 892
- **Position Value:** $23,058.20
- **Portfolio %:** 23.06%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-03 (Est: $0.60)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.63 | $0.87 | +37.4% |
| 2025Q2 | $0.57 | $0.78 | +35.9% |
| 2025Q1 | $0.67 | $0.92 | +36.5% |
| 2024Q4 | $0.46 | $0.63 | +37.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*